Welcome to our dedicated page for Arteris SEC filings (Ticker: AIP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Arteris, Inc. (Nasdaq: AIP) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Arteris describes itself as a global leader in system IP used in semiconductors, and its filings offer formal detail on the financial and operational aspects behind that business.
Among the key documents are current reports on Form 8-K, which Arteris uses to furnish press releases announcing quarterly financial results and other material events. For example, the company has filed 8-Ks referencing press releases on results for quarters ended June 30 and September 30, including metrics such as revenue, licensing and royalty performance, operating loss, and Remaining Performance Obligations. These filings give investors structured insight into how Arteris’ licensing, support and maintenance, and variable royalty revenue streams are evolving.
Users can also review other periodic reports, such as Forms 10-Q and 10-K when available, to understand topics like segment performance, risk factors, and detailed financial statements that complement the high-level figures cited in press releases. For those interested in governance and ownership, SEC filings are the place where proxy statements and beneficial ownership reports would appear.
Stock Titan enhances this information by pairing real-time updates from EDGAR with AI-powered summaries that highlight the main points of lengthy filings. Instead of reading every line of a multi-page 10-K or 10-Q, users can rely on AI explanations to quickly identify revenue trends, key risks, and notable changes. The platform also surfaces insider transaction reports on Form 4 when filed, helping investors monitor trading activity by Arteris officers and directors.
By using this page, investors and researchers can efficiently navigate Arteris’ official SEC disclosures, from earnings-related 8-Ks to comprehensive annual and quarterly reports, supported by AI tools that make complex documents easier to interpret.
Arteris, Inc. insider notice reports a proposed sale under Rule 144 of 11,841 common shares with an aggregate market value of $130,014.18. The shares were acquired on 01/28/2021 through previously exercised stock options and were paid for in cash. The filing names Morgan Stanley Smith Barney LLC Executive Financial Services as the broker and lists an approximate sale date of 10/06/2025 on NASDAQ. The notice also discloses a prior sale on 08/05/2025 of 6,909 shares generating $97,699.48, and includes the standard Rule 10b5-1 representation and signature attestation.
Notice of proposed insider sale: This Form 144 reports a planned sale of 17,200 common shares through Morgan Stanley Smith Barney LLC with an aggregate market value of $188,856.00. The shares were acquired as Restricted Stock Units on 09/03/2024 and listed as available for sale with an approximate sale date of 10/06/2025 on NASDAQ. The filing also discloses multiple recent sales by the same person under 10b5-1 plans totaling tens of thousands of shares across 07/29/2025 through 10/03/2025, with individual gross proceeds shown per trade. The filer represents they know of no undisclosed material adverse information.
Arteris, Inc. (AIP) filed a Form 144 reporting a proposed Rule 144 sale of 100,000 common shares through Morgan Stanley Smith Barney LLC on the 10/06/2025, with an aggregate market value of $1,098,000.00 based on the filing. The shares were acquired in a private issuance from the issuer on 11/05/2013 and the filing says payment was made by check on that date.
The filing also discloses multiple sales by the same person (and related 10b5-1 plans) during the past three months, including a 94,245-share 10b5-1 sale on 08/05/2025 and other transactions totaling material proceeds. The filer attests they have no undisclosed material adverse information.
Arteris, Inc. filing of Form 144 notifies the market of a proposed sale of 4,750 common shares through Morgan Stanley Smith Barney LLC with an aggregate market value of $53,485.00. The sale is to occur on or about 10/03/2025 on NASDAQ. The shares were acquired as Restricted Stock Units on 10/01/2025 from the issuer and are listed as 4,750 units in the notice. The filing also discloses multiple recent sales by the same person, Paul Alpern, during the past three months with individual sale dates and proceeds provided.
The form includes the seller's representation that no undisclosed material adverse information is known and provides broker contact details; it documents compliance with Rule 144 sale notice requirements rather than presenting operational or financial performance data.
Arteris, Inc. filed a Form 144 disclosing a proposed sale of 1,554 common shares to be executed through Morgan Stanley Smith Barney LLC on 10/03/2025 on NASDAQ. The filing states these shares were acquired as Restricted Stock Units from the issuer on 10/01/2025 and were paid/settled on the same date. The filing also lists multiple consummated sales by Laurent Moll during the prior three months, including sales of 42,692 shares on 09/02/2025 and other 10b5-1 plan sales totaling tens of thousands of shares across July–October 2025. The company reports 42,649,917 shares outstanding, and the proposed sale represents a small fraction of that total.
Arteris, Inc. (AIP) filed a Form 144 notifying the proposed sale of 11,821 common shares with an aggregate market value of $133,104.46. The shares are to be sold on or about 10/03/2025 on NASDAQ.
The filing shows these shares were acquired as Restricted Stock Units from the issuer on 10/01/2025. The filer reported multiple sales in the prior three months, including sales of 94,245 shares on 08/05/2025 (gross proceeds $1,271,120.01) and other transactions on 09/02/2025, 09/04/2025, and 10/02/2025.
Paul L. Alpern, Vice President and General Counsel of Arteris, Inc. (AIP), reported transactions dated 10/01/2025 executed under a 10b5-1 trading plan adopted on June 5, 2025. The reporting person acquired 5,000 shares (transaction code M) at an effective price of $0.56 and sold 5,000 shares (transaction code S) at a weighted average price of $10.3089, with sale prices ranging from $10.16 to $10.51. After the transactions, the report shows 73,587 shares beneficially owned as to the non-derivative holdings and 85,000 shares when including derivative securities. The derivative shown is an option with a $0.56 exercise price exercisable beginning 10/01/2025 and expiring 10/23/2029. The filing is signed and dated 10/03/2025.
Arteris, Inc. reported a Form 144 notice showing an intended sale of 19,060 shares of its common stock by a holder using Morgan Stanley Smith Barney LLC as broker, with an aggregate market value of $200,130.00. The filing states the shares were acquired as Restricted Stock Units on 09/03/2024 and the planned approximate sale date is 10/02/2025 on NASDAQ. The issuer has 42,649,917 shares outstanding per the filing. The notice also lists multiple recent sales by the same person under a 10b5-1 plan and direct sales between 07/03/2025 and 09/09/2025, totaling tens of thousands of shares and several hundred thousand dollars in gross proceeds.
Paul L. Alpern, who is listed as a director and as an officer (VP and General Counsel) of Arteris, Inc. (AIP), reported a set of transactions dated 09/15/2025 made pursuant to a 10b5-1 trading plan adopted June 5, 2025. The filing shows an acquisition of 10,000 common shares at a $0.56 exercise/conversion price and a simultaneous sale of 10,000 common shares at a weighted average price of $8.8805 (sales executed across $8.73–$8.97). After these transactions, the reporting person’s direct beneficial ownership in common stock was reported as 73,587 shares. The derivative table shows the reporting person holds options exercisable 09/15/2025 with a $0.56 strike for 10,000 underlying shares and reports 90,000 derivative securities beneficially owned following the reported transactions. The filing is signed 09/17/2025.
Form 144 notice for Arteris, Inc. (AIP) reports a proposed sale of 10,000 common shares to be executed through Morgan Stanley Smith Barney on 09/15/2025 with an aggregate market value of $87,500. The filer acquired these shares the same day by exercise of stock options and paid in cash. The filing also discloses insider sales over the prior three months totaling 9,448 shares for aggregate gross proceeds of $85,168.03, executed under both regular and Rule 10b5-1 plans. The notice includes the filer’s representation that no undisclosed material adverse information is known.